Many patients notice improvements in energy and recovery within the first few weeks, but the cellular marker improvement is dependent on baseline oxidative stress
This gastric emptying delay is most pronounced early in therapy and may diminish with continued use
Important considerations before combining these medications include: Absolute contraindications : The combination should be avoided in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, during or within 14 days of MAOI use, personal/family history of MTC or MEN2, pregnancy, breastfeeding, or severe gastrointestinal disease Cardiovascular risk assessment : Phentermine increases heart rate and blood pressure, which requires careful monitoring with baseline and follow-up measurements of vital signs and possibly EKG if cardiac history exists Gastrointestinal tolerability : Tirzepatide commonly causes nausea, vomiting, and diarrhea, which may be compounded by phentermine's effects Medication interactions : Tirzepatide may reduce the effectiveness of oral contraceptives during initiation and dose escalation
Additionally, clusters where more than 75% of cells originated from one batch were discarded
The goal is to maximize tolerability and clinical outcomes within the framework of personalized medicine